
CLAIMS

WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12C inhibitor of formula (I):



Formula (I)

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer in a subject in need thereof,

wherein:

X is a 4-12 membered saturated or partially saturated monocyclic, bridged or spirocyclic ring, wherein the saturated or partially saturated monocyclic ring is optionally substituted with one or more R^8;

Y is a bond, O, S or NR^5;

R^1 is $–C(O)C(R^A)$ ⋯ $C(R^B)_p$ or $–SO_2C(R^A)$ ⋯ $C(R^B)_p$;

R^2 is hydrogen, alkyl, hydroxyalkyl, dihydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, -Z-NR^5R^{10}, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, or heteroarylalkyl, wherein each of the

Z, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, and heteroarylalkyl may be optionally substituted with one or more R^9;

each Z is $C_1 – C_4$ alkylene;

each R^3 is independently $C_1 – C_3$ alkyl, oxo, haloalkyl, hydroxyl or halogen;

L is a bond, -C(O)-, or $C_1 – C_3$ alkylene;

R^4 is hydrogen, cycloalkyl, heterocyclyl, aryl, aralkyl or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, aralkyl and heteroaryl may be optionally substituted with one or more R^6, R^7 or R^8;

each R^5 is independently hydrogen or $C_1 – C_3$ alkyl;

R^6 is cycloalkyl, heterocyclyl, heterocyclylalkyl, aryl, or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, or heteroaryl may be optionally substituted with one or more R^7;

each R^7 is independently halogen, hydroxyl, $C_1 – C_6$ alkyl, cycloalkyl, alkoxy, haloalkyl, amino, cyano, heteroalkyl, hydroxyalkyl or Q-haloalkyl, wherein Q is O or S;

R^8 is oxo, $C_1 – C_3$ alkyl, $C_2 – C_4$ alkynyl, heteroalkyl, cyano, $-C(O)OR^5$, $-C(O)N(R^5)_2$, $-N(R^5)_2$, wherein the $C_1 – C_3$ alkyl may be optionally substituted with cyano, halogen, $-OR^5$, $-N(R^5)_2$, or heteroaryl;


each R^9 is independently hydrogen, oxo, acyl, hydroxyl, hydroxyalkyl, cyano, halogen, $C_1 – C_6$ alkyl, aralkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, alkoxy, dialkylaminyl, dialkylamidoalkyl, or dialkylaminylalkyl, wherein the $C_1 – C_6$ alkyl may be optionally substituted with cycloalkyl;

each R^{10} is independently hydrogen, acyl, $C_1 – C_3$ alkyl, heteroalkyl or hydroxyalkyl;

R^{11} is haloalkyl;

R^A is absent, hydrogen, deuterium, cyano, halogen, $C_1 – C_3$ alkyl, haloalkyl, heteroalkyl, -$C(O)N(R^5)_2$, or hydroxyalkyl;


each R^B is independently hydrogen, deuterium, cyano, $C_1 – C_3$ alkyl, hydroxyalkyl, heteroalkyl, $C_1 – C_3$ alkoxy, halogen, haloalkyl, -ZNR^5R^{11}, -$C(O)N(R^5)_2$, -$NHC(O)C_1 – C_3$ alkyl, -$CH_2NHC(O)C_1 – C_3$ alkyl, heteroaryl, heteroarylalkyl, dialkylaminylalkyl, or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and $C_1 – C_3$ alkyl, wherein the heteroaryl or the heteroaryl portion of the heteroarylalkyl is optionally substituted with one or more R^7;

when  is a triple bond then R^A is absent, R^B is present and p equals one,
or when  is a double bond then R^A is present, R^B is present and p equals two, or R^A, R^B and the carbon atoms to which they are attached form a 5-8 membered partially saturated cycloalkyl optionally substituted with one or more R^7;

m is zero or an integer between 1 and 2; and

p is one or two.

2. The use of claim 1, wherein R^1-X is:



wherein the piperazinyl ring is optionally substituted with R^8.

3. The use of claim 2, wherein R^1 is $-C(O)C(R^A)\equiv C(R^B)_p$

4. The use of claim 3, wherein $\equiv$ is a triple bond and R^A is absent, p is one and R^B is $C_1 - C_3$ alkyl, hydroxyalkyl or $C_1 - C_3$ alkoxy.

5. The use of claim 3, wherein $\equiv$ is a double bond and R^A is hydrogen and R^B is hydrogen.

6. The use of claim 3, wherein $\equiv$ is a double bond and R^A is hydrogen, p is two and at least one R^B is independently deuterium, cyano, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, $-NHC(O)C_1 - C_3$ alkyl or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy or $C_1 - C_3$ alkyl.

7. The use of claim 6, wherein the at least one R^B is halogen.

8. The use of claim 6, wherein the at least one R^B is haloalkyl.

9. The use of claim 6, wherein the at least one R^B is $-ZNR^5R^{11}$.

10. The use of claim 9, wherein Z is methylene, R^5 is methyl and R^{11} is trifluoromethyl.

11. The use of claim 6, wherein the at least one R^B is cyano.

12. The use of claim 6, wherein the at least one R^B is hydroxyalkyl.

13. The use of claim 6, wherein the at least one R^B is heteroalkyl.

14. The use of claim 13, wherein the heteroalkyl is methoxymethyl.

15. The use of claim 6, wherein the at least one R^B is -C(O)N(R^5)$_2$, wherein each R^5 is hydrogen.

16. The use of claim 6, wherein the at least one R^B is -C(O)N(R^5)$_2$, wherein each R^5 is C_1 – C_3 alkyl.

17. The use of claim 6, wherein the at least one R^B is heteroaryl optionally substituted with one or more R^7.

18. The use of claim 17, wherein the heteroaryl is pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl, each substituted with one or more R^7.

19. The use of claim 6, wherein the at least one R^B is heteroarylalkyl optionally substituted with one or more R^7.

20. The use of claim 19, wherein the heteroaryl portion of the heteroarylalkyl is pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl, each optionally substituted with one or more R^7.

21. The use of claim 6, wherein the at least one R^B is heterocyclylalkyl substituted with one or more R^7.

22. The use of claim 21, wherein the heterocyclyl portion of the heterocyclylalkyl is azetindinyl, pyrrolidinyl, piperidinyl piperazinyl or morpholinyl, each substituted with one or more groups independently selected from halogen, hydroxyl, alkoxy or C_1 – C_3 alkyl.

23. The use according to any of claims 6-22, wherein the double bond is in the E configuration.

24. The use according to any of claims 6-22, wherein the double bond is in the Z configuration..

25. The use of claim 6, wherein  is a double bond and p is two, each R^B is hydrogen, and R^A is deuterium, cyano, halogen, haloalkyl, heteroalkyl, $-C(O)N(R^5)_2$, or hydroxyalkyl.

26. The use of claim 25, wherein R^A is halogen.

27. The use of claim 25, wherein R^A is haloalkyl.

28. The use of claim 25, wherein R^A is cyano.

29. The use of claim 25, wherein R^A is heteroalkyl.

30. The use of claim 29, wherein the heteroalkyl is methoxymethyl.


31. The use of claim 29, wherein the heteroalkyl is alkoxy.

32. The use of claim 25, wherein R^A is $-C(O)N(R^5)_2$, wherein each R^5 is hydrogen.

33. The use of claim 25, wherein R^A is hydroxyalkyl.

34. The use of claim 2, wherein  is a double bond and p is two, one R^B is hydrogen, the second R^B is dialkylaminylalkyl, and R^A is halogen.

35. The use of claim 2, wherein  is a double bond and p is two, each R^B is deuterium, and R^A is deuterium.

36. The use of claim 2, wherein when  is a double bond and p is two, one R^B is hydrogen and R^A and one R^B and the carbon atoms to which they are attached form a 5-8 membered partially saturated cycloalkyl substituted with oxo.

37. The use of according to any one of claims 2-36, wherein Y is O.

38. The use according to any one of claims 2-37, wherein R^2 is selected from the group consisting of hydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, $-ZNR^5R^{10}$, heterocyclyl and heterocyclylalkyl, wherein each of the Z, heterocyclyl or heterocyclylalkyl are independently optionally substituted with R^9.

39. The use of claim 38, wherein R^2 is heterocyclylalkyl optionally substituted with one or more R^9.

40. The use of claim 39, wherein the heterocyclyl of the heterocyclylalkyl is independently azetidinyl, methylazetidinyl, difluoroazetidinyl, tetrahydropyran, pyrrolidinyl, methylpyrrolidinyl, diemethylpyrrolidinyl, isopropylpyrrolidinyl, cycloalkylalkylpyrrolidinyl, hydroxypyrrolindinyl, fluoropyrrolidinyl, difluoropyrrolidinyl, (N-methyl)fluoropyrrolidinyl, (N-methyl)difluoropyrrolidinyl, methoxyethylpyrrolidinyl, (N-methyl)methoxypyrrolidinyl, piperazinyl, dimethylaminylpyrrolidinyl, morpholinyl, methylmorpholinyl, 1,4-oxazepanyl, piperdinyl, methylpiperidinyl acylpiperdinyl, cyanopiperdinyl, cycloalkylpiperdinyl, halopiperdinyl, dihalopiperdinyl, fluoropiperdinyl, difluoropiperdinyl, alkoxypiperdinyl, pyrrolidonyl, piperidinonyl, thiomorpholinyl-1,1-dioxide, 3-azabicyclo[3.1.0]hexanyl, oxa-5-azabicyclo[2.2.1]heptan-5-yl, or azabicyclo[2.2.1]heptan-2-yl.

41. The use of claim 40, wherein the (N-methyl)difluoropyrrolidinyl is 3,3-difluoro-1-methylpyrrolidinyl.

42. The use of claim 40, wherein the heterocyclyl is N-methylpyrrolidinyl.

43. The use of claim 38, wherein R^2 is dialkylaminylalkyl optionally substituted with one or more R^9.

44. The use according to any one of claims 2-43, wherein R^4 is aryl optionally substituted with one or more R^7.

45. The use of claim 44, wherein the aryl is selected from the group consisting of phenyl and naphthyl optionally substituted with one or more R^7.

46. The use of claim 45, wherein the phenyl and the naphthyl are each optionally substituted with one or more R^7 selected from the group consisting of halogen, hydroxyl, C1- C6 alkyl, haloalkyl, Q-haloalkyl, and alkoxy.

47. The use of claim 46, wherein R^7 is selected from the group consisting of halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl, hydroxyl and cyano.

48. The use according to any one of claims 2-43, wherein R^4 is heteroaryl.

49. The use according to any one of claims 2-43, wherein R^4 is aralkyl optionally substituted with one or more R^7.

50. The use according to any one of claims 2-49, wherein m is zero.

51. The use according to any one of claims 2-50, wherein L is a bond.













52. The use according to any one of claims 2-51, wherein R^8 is heteroalkyl, $C_2 – C_4$ alkynyl, or $C_1 – C_3$alkyl optionally substituted with $-OR^5$, cyano or heteroaryl.













53. The use of claim 52, wherein R^8 is $C_1 – C_3$ alkyl optionally substituted with cyano.












54. The use of claim 52, wherein R^8 is cyanomethyl.









55. The use according to any one of claims 52-54, wherein X is substituted with one R^8.







56. The use of claim 1, wherein the KRas G12C inhibitor is:













,

,

,

,

,

,

,

,

,

,

,

,













,

,

,

,

,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,














,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,










,

,

,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,













,

,

,

,

,

,

,

,

,

,

,

,













,


,


,



,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,



HO
F
,



HO
F
F
,



H
CH3
,



CN
CF3
,



CN
CF3
,



NC
CF3
,



HO
,














HO
S
CF3
,


HO
OH
,


HO
OH
,


HO
OH
,





NC
OH
,





,

,

,

,

,

,

,

,

,

,

,

,




,




,













,














,

,

,


,

,

,


,

,

,


,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,













,

,

,


,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,













,














,

,

,

,

,

,

,

,

,

,

,

,













,













,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,













,


,

,














,

,

,

,

,

,

,

,

,

,

,

.


,

,

,

,

,

,

,

,

,

,

,

.


,

,

,

,

,

,

,

,

,

,

,

,



,

,
















,

















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,

,

,

,













,













,
















,
















,

,

,

,

,

,

,

,

,

,

,

,











,

,

,

,

,

,

,

,

,

,

,

.













,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,













 ,
 ,
 ,
 ,
 ,
 ,
 ,
 ,
 ,
 ,
 ,
 ,
 ,
 ,
 ,











,

,

,

,

,

,

,

,

,

,

,

,

,















,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,













,

,


,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,

,

,

,

,

,

,





,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

and


or pharmaceutically acceptable salts thereof.

57. The use of claim 1, wherein the KRas G12C inhibitor is selected from the group consisting of:


, 
, 
, and 


or pharmaceutically acceptable salts thereof.

58. The use of claim 1, wherein the KRas G12C inhibitor is:




or a pharmaceutically acceptable salt thereof.

59. The use of claim 1, wherein the KRas G12C inhibitor is:




or a pharmaceutically acceptable salt thereof.

60. The use of claim 1, wherein the KRas G12C inhibitor is:



or a pharmaceutically acceptable salt thereof.

61. The use of claim 1, wherein the KRas G12C inhibitor is:



or a pharmaceutically acceptable salt thereof.

62. The use according to any one of claims 1-61, wherein the SHP-2 inhibitor is SHP-099 (6-(4-Amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine dihydrochloride); RMC-4550 (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl)methanol), RMC-4360 or TNO155 (Novartis).

63. The use of claim 62, wherein the SHP-2 inhibitor is SHP-099.

64. The use of claim 62, wherein the SHP-2 inhibitor is RMC-4550.

65. The use of claim 62, wherein the SHP-2 inhibitor is RMC-4360 or TNO155.

66. The use according to any one of claims 1-65, wherein the SHP-2 inhibitor and the KRAS G12C inhibitor are to be administered on the same day.

67. The use according to any one of claims 1-65, wherein the SHP-2 inhibitor and the KRAS G12C inhibitor are to be administered on different days.

68. The use according to any one of claims 1-67, wherein the KRas G12C inhibitor is to be administered at a maximum tolerated dose.

69. The use according to any one of claims 1-67, wherein the SHP-2 inhibitor and the KRAS G12C inhibitor are each to be administered at a maximum tolerated dose.

70. The use according to any one of claims 1-69, wherein the therapeutically effective amount of the combination of the SHP-2 inhibitor and the KRAS G12C inhibitor results in an increased duration of overall survival, an increased duration of progression free survival, an increase in tumor growth regression, an increase in tumor growth inhibition or an increased duration of stable diseasein the subjects relative to treatment with only the KRas G12C inhibitor.

71. A pharmaceutical composition, comprising a therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRas G12C inhibitor of Formula (I), Formula I-A or Formula I-B according to any one of claims 1-61, and a pharmaceutically acceptable excipient.

72. A method for inhibiting KRas G12C activity in a cell, comprising contacting the cell in which inhibition of KRas G12C activity is desired with an effective amount of a SHP-2 inhibitor and a KRas G12C inhibitor compound of a Formula (I), Formula I-A or Formula I-B according

to any one of claims 1-61, pharmaceutical compositions or pharmaceutically acceptable salts thereof, wherein the SHP-2 inhibitor synergistically increases the sensitivity of the cancer cells to the KRas G12C inhibitor.

73. The method according to any one of claims 1-70 and 72, wherein the SHP-2 inhibitor synergistically increases the sensitivity of the cancer cells to the KRas G12C inhibitor.

74. Use of a compound of Formula (I), Formula I-A or Formula I-B or a pharmaceutically acceptable salt thereof according to any one of claims 1-61, in the manufacture of a medicament, for increasing the sensitivity of a cancer cell to a KRas G12C inhibitor compound of Formula (I), Formula I-A or Formula I-B, wherein the compound is to be administered to a subject undergoing KRas G12C treatment alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, a therapeutically effective amount of a SHP-2 inhibitor, wherein the SHP-2 inhibitor synergistically increases the sensitivity of the cancer cell to the KRas G12C inhibitor.

75. The use according to any of claims 73 and 74, wherein the therapeutically effective amount of the KRas G12C inhibitor in the combination is between about 0.01 to 100 mg/kg per day.

76. The use of claim 75, wherein the therapeutically effective amount of the KRas G12C inhibitor in the combination is between about 0.1 to 50 mg/kg per day.

77. The use according to any of claims 74-76, wherein the therapeutically effective amount of the SHP-2 inhibitor in the combination is between about 0.01 to 100 mg/kg per day.

78. The use of claim 77, wherein the therapeutically effective amount of the SHP-2 inhibitor in the combination is between about 0.1 to 50 mg/kg per day.

79. The use according to any one of claims 1-70 and 73 - 78, wherein the cancer is selected from the group consisting of Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma,

lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: gall bladder carcinoma, ampullary carcinoma, cholangiocarcinoma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial `carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma,


Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma.

80. The use of claim 73-79, wherein the cancer wherein the cancer is a KRas G12C-associated cancer.

81. The use of claims 80, wherein the cancer is non-small cell lung cancer.

82. A kit comprising the pharmaceutical composition of claim 71 for treating KRas G12C cancer in a subject.

83. A kit comprising: a) a pharmaceutical composition comprising a SHP-2 inhibitor and b) a pharmaceutical composition comprising a KRas G12C inhibitor of:



Formula (I)

or a pharmaceutically acceptable salt thereof:

wherein:

X is a 4-12 membered saturated or partially saturated monocyclic, bridged or spirocyclic ring, wherein the saturated or partially saturated monocyclic ring is optionally substituted with one or more R^8;

Y is a bond, O, S or NR^5;

R^1 is $–C(O)C(R^A)$ ------ $C(R^B)_p$ or $–SO_2C(R^A)$ ------ $C(R^B)_p$;

R^2 is hydrogen, alkyl, hydroxyalkyl, dihydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, -Z-NR^5R^{10}, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, or heteroarylalkyl, wherein each of the Z, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, and heteroarylalkyl may be optionally substituted with one or more R^9;

each Z is C_1 – C_4 alkylene;

each R^3 is independently C_1 – C_3 alkyl, oxo, haloalkyl, hydroxyl or halogen;

L is a bond, -C(O)-, or C_1 – C_3 alkylene;

R^4 is hydrogen, cycloalkyl, heterocyclyl, aryl, aralkyl or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, aralkyl and heteroaryl may be optionally substituted with one or more R^6, R^7 or R^8;

each R^5 is independently hydrogen or C_1 – C_3 alkyl;

R^6 is cycloalkyl, heterocyclyl, heterocyclylalkyl, aryl, or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, or heteroaryl may be optionally substituted with one or more R^7;

each R^7 is independently halogen, hydroxyl, C_1 – C_6 alkyl, cycloalkyl, alkoxy, haloalkyl, amino, cyano, heteroalkyl, hydroxyalkyl or Q-haloalkyl, wherein Q is O or S;

R^8 is oxo, C_1 – C_3 alkyl, C_2 – C_4 alkynyl, heteroalkyl, cyano, -C(O)OR^5, -C(O)$N(R^5)_2$, -$N(R^5)_2$, wherein the C_1 – C_3 alkyl may be optionally substituted with cyano, halogen, -OR^5, -$N(R^5)_2$, or heteroaryl;

each R^9 is independently hydrogen, oxo, acyl, hydroxyl, hydroxyalkyl, cyano, halogen, C_1 – C_6 alkyl, aralkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, alkoxy, dialkylaminyl, dialkylamidoalkyl, or dialkylaminylalkyl, wherein the C_1 – C_6 alkyl may be optionally substituted with cycloalkyl;

each R^{10} is independently hydrogen, acyl, C_1 – C_3 alkyl, heteroalkyl or hydroxyalkyl;

R^{11} is haloalkyl;


R^A is absent, hydrogen, deuterium, cyano, halogen, C_1 – C_3 alkyl, haloalkyl, heteroalkyl, -C(O)$N(R^5)_2$, or hydroxyalkyl;

each R^B is independently hydrogen, deuterium, cyano, $C_1 – C_3$ alkyl, hydroxyalkyl, heteroalkyl, $C_1 – C_3$ alkoxy, halogen, haloalkyl, -ZNR^5R^{11}, -$C(O)N(R^5)_2$, -$NHC(O)C_1 – C_3$ alkyl, -$CH_2NHC(O)C_1 – C_3$ alkyl, heteroaryl, heteroarylalkyl, dialkylaminylalkyl, or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and $C_1 – C_3$ alkyl, wherein the heteroaryl or the heteroaryl portion of the heteroarylalkyl is optionally substituted with one or more R^7;

when  is a triple bond then R^A is absent, R^B is present and p equals one,
or when  is a double bond then R^A is present, R^B is present and p equals two, or R^A, R^B and the carbon atoms to which they are attached form a 5-8 membered partially saturated cycloalkyl optionally substituted with one or more R^7;


m is zero or an integer between 1 and 2; and

p is one or two.
or



Formula I-A

and pharmaceutically acceptable salts thereof, wherein R^1, R^3, R^4, R^5, R^{10}, L and m are as defined for Formula I, R^{11} is hydrogen, methyl or hydroxyalkyl, and the piperidinyl ring is optionally substituted with R^8 wherein R^8 is as defined for Formula I
or



Formula I-B

and pharmaceutically acceptable salts thereof, wherein R^1, R^3, R^4, L and m are as defined for Formula I, R^2 is heterocyclylalkyl optionally substituted with one or more R^9 where R^9 is as defined for Formula I, and the piperazinyl ring is optionally substituted with R^8, where R^8 is as defined for Formula I,

for treating a KRas G12C cancer in a subject.

84. The kit according to claim 82 or 83, further comprising an insert with instructions for administration of the pharmaceutical composition(s).